David Bahnsen Dividend Strategy
David Bahnsen – founder of The Bahnsen Group and author…
Sell
45
RDY Quote, Financials, Valuation and Earnings
Last price:
$13.63
Seasonality move
:
3.2%
Day range:
$13.56 - $13.71
52-week range:
$13.36 - $16.89
Dividend yield:
0.7%
P/E ratio:
21.79x
P/S ratio:
3.09x
P/B ratio:
3.06x
Volume:
1.5M
Avg. volume:
2M
1-year change:
-9.98%
Market cap:
$11.3B
Revenue:
$3.4B
EPS (TTM):
$0.62
Analysts' Opinion
-
Consensus RatingDr Reddy's Laboratories has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $15.64, Dr Reddy's Laboratories has an estimated upside of 15.01% from its current price of $13.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.11 representing -- downside risk from its current price of $13.60.
Fair Value
-
According to the consensus of 4 analysts, Dr Reddy's Laboratories has 15.01% upside to fair value with a price target of $15.64 per share.
RDY vs. S&P 500
-
Over the past 5 trading days, Dr Reddy's Laboratories has underperformed the S&P 500 by -1.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dr Reddy's Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dr Reddy's Laboratories has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Dr Reddy's Laboratories reported revenues of $989.4M.
Earnings Growth
-
Dr Reddy's Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Dr Reddy's Laboratories reported earnings per share of $0.20.
Enterprise value:
11.2B
EV / Invested capital:
0.00x
Price / LTM sales:
3.09x
EV / EBIT:
12.56x
EV / Revenue:
3.06x
PEG ratio (5yr expected):
2.34x
EV / Free cash flow:
141.54x
Price / Operating cash flow:
143.00x
Enterprise value / EBITDA:
10.33x
Gross Profit (TTM):
$2.2B
Return On Assets:
13.09%
Net Income Margin (TTM):
17.46%
Return On Equity:
18.24%
Return On Invested Capital:
17.18%
Operating Margin:
22.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $3B | $3.3B | $3.7B | $866.5M | $989.4M | |
| Gross Profit | $1.7B | $1.9B | $2.2B | $506.9M | $580.6M | |
| Operating Income | $695.6M | $788.3M | $799.8M | $203M | $221.4M | |
| EBITDA | $882.4M | $1B | $1.1B | $269.3M | $287.4M | |
| Diluted EPS | $0.55 | $0.59 | $0.62 | $0.20 | $0.20 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $2.2B | $2.3B | $2.9B | $2.9B | |
| Total Assets | $3.4B | $3.8B | $3.7B | $4.5B | $5.6B | |
| Current Liabilities | $1B | $1.1B | $1B | $1.1B | $1.5B | |
| Total Liabilities | $1.1B | $1.2B | $1.1B | $1.3B | $1.9B | |
| Total Equity | $2.3B | $2.6B | $2.7B | $3.2B | $3.7B | |
| Total Debt | $230.2M | $337.6M | $184.5M | $193.4M | $538.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $601.3M | $664.3M | $383.3M | $54.4M | $76.6M | |
| Cash From Investing | -$607.3M | -$551.8M | -$619.7M | -$193.2M | -$60.7M | |
| Cash From Financing | -$207M | -$99.1M | $254.2M | $64.2M | $4.4M | |
| Free Cash Flow | $361.9M | $359.1M | $79.3M | -$4.8M | -$26.4M | |
RDY
Sector
Market Cap
$11.3B
$43.9M
Price % of 52-Week High
--
48.46%
Dividend Yield
0.7%
0%
Shareholder Yield
-0.68%
-0.75%
1-Year Price Total Return
-9.98%
-34.83%
Beta (5-Year)
0.500
0.748
Dividend yield:
0.7%
Annualized payout:
$0.10
Payout ratio:
12.3%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$13.85
200-day SMA
Sell
Level
$15.11
Bollinger Bands (100)
Sell
Level
14.15 - 15.67
Chaikin Money Flow
Sell
Level
-11.6M
20-day SMA
Sell
Level
$13.98
Relative Strength Index (RSI14)
Sell
Level
36.51
ADX Line
Sell
Level
25.05
Williams %R
Neutral
Level
-64.7059
50-day SMA
Sell
Level
$14.63
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
20.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.4998)
Buy
CA Score
(Annual)
Level (1.7944)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-3.7895)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Stock Forecast FAQ
In the current month, RDY has received 1 Buy ratings 2 Hold ratings, and 1 Sell ratings. The RDY average analyst price target in the past 3 months is $15.64.
-
Where Will Dr Reddy's Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dr Reddy's Laboratories share price will rise to $15.64 per share over the next 12 months.
-
What Do Analysts Say About Dr Reddy's Laboratories?
Analysts are divided on their view about Dr Reddy's Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dr Reddy's Laboratories is a Sell and believe this share price will drop from its current level to $13.11.
-
What Is Dr Reddy's Laboratories's Price Target?
The price target for Dr Reddy's Laboratories over the next 1-year time period is forecast to be $15.64 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RDY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dr Reddy's Laboratories is a Hold. 2 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RDY?
You can purchase shares of Dr Reddy's Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dr Reddy's Laboratories shares.
-
What Is The Dr Reddy's Laboratories Share Price Today?
Dr Reddy's Laboratories was last trading at $13.63 per share. This represents the most recent stock quote for Dr Reddy's Laboratories. Yesterday, Dr Reddy's Laboratories closed at $13.60 per share.
-
How To Buy Dr Reddy's Laboratories Stock Online?
In order to purchase Dr Reddy's Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Netflix a Buy, Sell or Hold?
If there is one company that can be termed a…
Why Is Tesla Stock Falling?
Tesla stock reached an all-time high of $479.86 on December…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 35x
Alerts
Buy
87
PCOR alert for Feb 18
Procore Technologies [PCOR] is up 0.45% over the past day.
Buy
54
DKNG alert for Feb 18
DraftKings [DKNG] is down 5.12% over the past day.
Sell
30
TWLO alert for Feb 18
Twilio [TWLO] is down 2.28% over the past day.
